The Press Office provides journalists with information on the diverse range of subjects that are relevant to the pharmaceutical industry. Our role is to ensure that any type of media is able to have access to the industry perspective and opinion.
GENEVA: On the occasion of the 5th anniversary of the World Health Organization’s roadmap on NTDs and the London Declaration, IFPMA released today its latest report “Doing our part – Innovating to fight Neglected Tropical Diseases” that provides the most up-to-date record of active research and development (R&D) projects for the next generation of medicines and vaccines for NTDs[i].Read more
The Association of the British Pharmaceutical Industry (ABPI) have issued the following statement on the calling of a snap General Election.Read more
The Association of the British Pharmaceutical Industry (ABPI) has responded to today’s House of Lords Long-Term Sustainability of the NHS Committee report.Read more
In a new snapshot survey of leading pharmaceutical businesses in the UK, companies have said that changes to the way the National Institute for Health & Care Excellence (NICE) and NHS England (NHSE) assess new medicines, coming in to effect today (1 April 2017), will decrease access to the latest treatments, with new medicines for cancer set to be impacted the most.Read more
The NHS has today (31 March) published its 'Next Steps On The NHS Five Year Forward View'. Read more
The Association of the British Pharmaceutical Industry (ABPI) has responded to today’s triggering of Article 50 of the Lisbon Treaty by Prime Minister Theresa May, officially starting the process of the United Kingdom (UK) negotiating its departure from the European Union (EU).Read more
New data shows research and development spend up to £254 million and a revised consent to disclose figure of 55%.
After participating in The Independent Review of the Individual Patient Funding Request (IPFR) Process, ABPI Cymru Wales has responded to Vaughan Gething, AM, Cabinet Secretary for Health, Well-being and Sport and the Welsh Government’s statement on the review.Read more
Parliamentary Under-Secretary of State at the Department for Business, Energy and Industrial Strategy, Lord Prior of Brampton, has today visited AstraZeneca’s Macclesfield Pharmaceutical Manufacturing Facility.Read more
On 1 February 2017, a public-private consortium was launched to facilitate the transition towards outcomes-focused healthcare systems across Europe. A wealth of emerging data from evolving data sources provides an opportunity for healthcare systems to measure outcomes that matter to patients, allowing resources to be focused on highly effective treatments. Over the next two years, the Big Data for Better Outcomes, Policy Innovation, and Healthcare Systems Transformation (DO>IT) consortium will coordinate the IMI2 Big Data for Better Outcomes (BD4BO) programme, identifying and addressing opportunities for data-driven healthcare system transformation based on input from healthcare systems stakeholders and on knowledge, data and tools developed in the BD4BO disease specific projects (Alzheimer’s Disease, hematologic malignancies, cardiovascular diseases, prostate cancer, etc.).Read more